Axitan Limited, a biotech company specializing in the development of endolysin enzyme products as antibiotic alternatives in animal feed, has appointed Gonzalo Prat as its new vice president of sales & marketing. Prat, based in Chesterfield, Missouri, will lead the global market expansion for Axitan’s portfolio of endolysin-based products, including its first commercial product for the poultry industry, FORC3.
Alfred Zimmerman, Axitan’s CEO, expressed confidence in Prat's extensive experience and commercial success across various livestock sectors during his 18-year tenure at Novus International, where he was most recently senior managing director for the Americas. Prat will be instrumental in building on Axitan’s current momentum, especially as the company moves forward with its mission of replacing antibiotics in animal feed with innovative endolysin technology.
In his new role, Prat emphasized the importance of Axitan’s role in the sustainable production of livestock and the potential of endolysin technology to address critical pathogen challenges without compromising productivity.
Axitan has been a leader in incorporating endolysins into animal feed, with its flagship product, FORC3, designed to target Clostridium perfringens in poultry. The company is also working on additional endolysin-based solutions to combat pathogens in other livestock, supporting the industry's need for sustainable and effective alternatives to antibiotics.
